Gelonghui, January 19 | Guangshengtang (300436.SZ) said on the investor interactive platform that our innovative anti-COVID-19 drug, Thai Zhongding, has been successfully included in the scope of temporary medical insurance payments, paid in category B, and completed online registration in more than a dozen provinces and cities, including Beijing, Fujian, Hebei, and Shanghai. Currently, in order to deal with the risks posed by the COVID-19 variant JN.1, some provinces and municipalities have included Thai Zhongding in key drug reserve procurement. This is part of the normal sales and operation activities of enterprises, and there are no matters that should be disclosed but not disclosed.
广生堂(300436.SZ)：抗新冠创新药泰中定已成功纳入临时医保支付范围
Guangshengtang (300436.SZ): Thai Zhongding, an innovative anti-COVID-19 drug, has been successfully included in the scope of temporary health insurance payments
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.